elli kaplan, neurotrack @ aging2.0 | washington, dc (8 nov 2012)
DESCRIPTION
TRANSCRIPT
![Page 1: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/1.jpg)
![Page 2: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/2.jpg)
Alzheimer’s in the U.S.
![Page 3: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/3.jpg)
Alzheimer’s 2100
![Page 4: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/4.jpg)
Alzheimer’s drug market
SYMPTOM PREVENTIVE
0
![Page 5: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/5.jpg)
Multiple attempts
Alzheimer's Drug From Pfizer, J&J Fails in Late-Stage Trial
Lilly Halts Alzheimer's Drug Trial
Glaxo’s Avandia Fails to Benefit Alzheimer’s Patients
![Page 6: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/6.jpg)
$10B
PREVENTIVEDRUG MARKET
$1B
FAILED DRUGS
![Page 7: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/7.jpg)
The best time to treat Alzheimer’s
Disease is likely to be before
memory loss and tissue
destruction occurs…
![Page 8: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/8.jpg)
NORMAL BRAIN ALZHEIMER’S
![Page 9: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/9.jpg)
Alter the trajectory
disease progressio
n
time
Current standard of diagnosis
Preventive
3 years
![Page 10: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/10.jpg)
Our technology
EYETRACKING
NEWIMAGE
CHANGEDETECTION
3YEARS
EARLIER
![Page 11: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/11.jpg)
Alzheimer’s conversion
0 100
0%of high scorers
99.9%of low scorers
![Page 12: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/12.jpg)
20,000requiredpatients
100new clinical
trials each year
1Phase IV
approved therapy
Strategy
![Page 13: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/13.jpg)
the Alzheimer’s diagnostic
![Page 14: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/14.jpg)
Patents filed and pending
Worldwide license
Pilot discussions
today
![Page 15: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/15.jpg)
Team
Elli KaplanCEO
Colin McDonaldCMO
Dr. Stuart Zola
Dr. Beth Buffalo
Dr. Eugene Agichtein
Scientific Advisory
![Page 16: Elli Kaplan, Neurotrack @ Aging2.0 | Washington, DC (8 Nov 2012)](https://reader035.vdocuments.site/reader035/viewer/2022070304/54c1429e4a79591c0f8b458b/html5/thumbnails/16.jpg)
Next steps
Business development
Seed capital